Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2017

01-12-2017 | Thoracic Oncology

Comments on “An Investigation into the Serum Thioredoxin, Superoxide Dismutase, Malondialdehyde, and Advanced Oxidation Protein Products in Patients with Breast Cancer”

Authors: Maryam Khoubnasabjafari, MD, PhD, Khalil Ansarin, MD, Abolghasem Jouyban, PharmD, PhD

Published in: Annals of Surgical Oncology | Special Issue 3/2017

Login to get access

Excerpt

In an article by Kilic et al., published in this journal, serum thioredoxin, superoxide dismutase, malondialdehyde (MDA), and advanced oxidation protein products in breast cancer patients and those of healthy controls were measured.1 Further statistical analysis revealed an increased MDA level in the patient group.1 The findings about MDA agree with some previously reported data and disagree with other reports. The purpose of this communication is not to criticize the valuable work of Kilic et al. but rather to highlight wide variations of MDA levels and to note some considerations on sample collection, confounding factors on MDA level, the validity of its measurement methods, and reliability of MDA as a biomarker in cancer. …
Literature
1.
Kilic N, Taslipinar MY, Guney Y, et al. An investigation into the serum thioredoxine, superoxide dismutase, malondialdehyde, and advanced oxidation protein products in patients with breast cancer. Ann Surg Oncol. 2014;21:4139–43.CrossRefPubMed
2.
Okauchi Y, Kishida K, Funahashi T, Noguchi M, Ogawa T, Okita K, et al. Crosssectional and longitudinal study of association between circulating thiobarbituric acid-reacting substance levels and clinicobiochemical parameters in 1178 middle-aged Japanese men—the Amagasaki Visceral Fat Study. Nutr Metabol. 2011;8:82.CrossRef
3.
Gupta A, Srivastava S, Prasad R, Natu SM, Mittal B, NEGI MPS, et al. Oxidative stress in non-small cell lung cancer patients after chemotherapy: association with treatment response. Respirology. 2010;15:349–56.CrossRefPubMed
4.
Chole RH, Patil RN, Basak A, Palandurkar K, Bhowate R. Estimation of serum malondialdehyde in oral cancer and precancer and its association with healthy individuals, gender, alcohol, and tobacco abuse. J Cancer Res Ther. 2010;6:487–91.CrossRefPubMed
5.
Mahdavi R, Faramarzi E, Seyedrezazadeh E, Mohammad-Zadeh M, Pourmoghaddam M. Evaluation of oxidative stress, antioxidant status and serum vitamin C levels in cancer patients. Biol Trace Elem Res. 2009;130:1–6.CrossRefPubMed
6.
Chang D, Wang F, Zhao YS, Pan HZ. Evaluation of oxidative stress in colorectal cancer patients. Biomed Environ Sci. 2008;21:286-9.CrossRefPubMed
7.
Rasheed MH, Beevi SS, Geetha A. Enhanced lipid peroxidation and nitric oxide products with deranged antioxidant status in patients with head and neck squamous cell carcinoma. Oral Oncol. 2007;43:333–8.CrossRefPubMed
8.
Beevi SS, Rasheed MH, Geetha A. Evidence of oxidative and nitrosative stress in patients with cervical squamous cell carcinoma. Clin Chim Acta. 2007;375:119–23.CrossRefPubMed
9.
Gonenc A, Erten D, Aslan S, Akinci M, Sximsxek B, Torun M. Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease. Cell Biol Int. 2006;30:376–80.CrossRefPubMed
10.
Maldonado PA, Negrini LA, Kaizer RR, Zanin RF, Araujo MC, Battisti V, et al. Oxidative status in patients submitted to conization and radiation treatments for uterine cervix neoplasia. Clin Chim Acta. 2006;366:174–8.CrossRefPubMed
11.
Beevi SS, Rasheed MH, Geetha A. Evaluation of oxidative stress and nitric oxide levels in patients with oral cavity cancer. Jpn J Clin Oncol. 2004;34:379–85.CrossRefPubMed
12.
Akbulut H, Akbulut KG, Icli F, Büyükcelik A. Daily variations of plasma malondialdehyde levels in patients with early breast cancer. Cancer Detect Prev. 2003;27:122–6.CrossRefPubMed
13.
Bakan E, Taysi S, Polat MF, Dalga S, Umudum Z, Bakan N, et al. Nitric oxide levels and lipid peroxidation in plasma of patients with gastric cancer. Jpn J Clin Oncol. 2002;32:162–6.CrossRefPubMed
14.
Subapriya R, Kumaraguruparan R, Ramachandran CR, Nagini S. Oxidant-antioxidant status in patients with oral squamous cell carcinomas at different intraoral sites. Clin Biochem. 2002;35:489–93.CrossRefPubMed
15.
Hristozov D, Gadjeva V, Vlaykova T, Popova S, Dimitrov G. Evaluation of oxidative stress in patients with cancer. Arch Phys Biochem. 2001;109:331–6.CrossRef
16.
Geber M, Astre C, Segala C, Saintot M, Scali J, Simony-Lafontaine J, et al. Oxidant-antioxidant status alterations in cancer patients: relationship to tumor progression. J Nutr. 1996;126:1201S–7S.
17.
Kinght JA, Smith SE, Kinder VE, Anstall HB. Reference intervals for plasma lipoperoxides: age-, sex-, and specimen-related variations. Clin Chem. 1987;33:2289–91.
18.
Polat MF, Taysi S, Gul M, Cikman O, Yilmaz I, Bakan E, et al. Oxidant-antioxidant status in blood of patients with malignant breast tumor and benign breast disease. Cell Biochem Funct. 2002;20:327–31.CrossRefPubMed
19.
Schoenmakers AW, Tarladgis BG. Reliability of the thiobarbituric acid test in the presence of inorganic ions. Nature. 1966;210:1153.CrossRef
20.
Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta. 1978;90:37–43.CrossRefPubMed
21.
Hackett C, Linley-Adams M, Lloyd B, Walker V. Plasma malondialdehyde: a poor measure of in vivo lipid peroxidation. Clin Chem. 1988;34:208.PubMed
22.
Kikugawa K, Kojima T, Yamaki S, Kosugi H. Interpretation of the thiobarbituric acid reactivity of rat liver and brain homogenates in the presence of ferric ion and ethylenediaminetetraacetic acid. Anal Biochem. 1992;202:249–55.CrossRefPubMed
23.
Antus B, Harnasi G, Drozdovszky O, Barta I. Monitoring oxidative stress during chronic obstructive pulmonary disease exacerbations using malondialdehyde. Respirology. 2014;19:74–9.CrossRefPubMed
24.
Halliwell B, Gutteridge JMC. Formation of a thiobarbituric-acid-reactive substance from deoxyribose in the presence of iron salts the role of superoxide and hydroxyl radicals. FEBS Lett. 1981;128:343–6.CrossRef
25.
Wade CR, van Rij AM. Plasma malondialdehyde, lipid peroxides, and the thiobarbituric acid reaction. Clin Chem. 1989;35:336.PubMed
26.
Poubelle P, Chainti-Euil J, Besadoux J, Boitman F, Simon L, Crastes de Paulet A. Plasma lipoperoxides and aging. Biomedicine. 1982;36:164–6.
27.
Wasowicz W, Neve J, Peretz A. Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: Importance of extraction pH and influence of sample preservation and storage. Clin Chem. 1993;39:2522–6.PubMed
28.
Gutteridge JMC. Free-radical damage to lipids, amino acids, carbohydrates and nucleic acids determined by thiobarbituric acid reactivity. Int J Biochem. 1982;14:649–53.CrossRefPubMed
29.
Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978;12:302–10.CrossRef
30.
Lepage P, Heckel C, Humbert S, Stahl S, Rautmann G. Preparative steps necessary for the accurate measurement of malondialdehyde by high-performance liquid chromatography. Anal Biochem. 1991;197:277–83.CrossRefPubMed
31.
Almandos ME, Giannini DH, Ciarlo AS, Boeri RL. Formaldehyde as an interference of the 2-thiobarbituric acid test. J Sci Food Agric. 1986;37:54–8.CrossRef
32.
Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radical Biol Med. 1990;9:515–40.CrossRef
33.
Cheeseman KH, Beavis A, Esterbauer H. Hydroxyl radical induced iron-catalysed degradation of 2-deoxyribose. Quantitative determination of malondialdehyde. Biochem J. 1988;252:649–53.CrossRefPubMedPubMedCentral
34.
Diczfalusy U, Falardeau P, Hammarstrom S. Conversion of prostaglandin endoperoxides to C17-hydroxy acids catalyzed by human platelet thromboxane synthase. FEBS Lett. 1977;84:271–4.CrossRefPubMed
35.
Bucknall T, Edwards HE, Kemsley KG, Moore JS, Phillips GO. The formation of malondialdehyde in irradiated carbohydrates. Carbohydrate Res. 1978;62:49–59.CrossRef
36.
Cohn JS. Oxidized fat in the diet, postprandial lipaemia and cardiovascular disease. Curr Opin Lipidol. 2002;13:19–24.CrossRefPubMed
37.
Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem. 1997;43:1209–14.PubMed
38.
Lapenna D, Ciofani G, Pierdomenico SD, Giamberardino MA, Cuccurullo F. Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma. Free Rad Biol Med. 2001;31:331–5.CrossRefPubMed
39.
Martin JF, Greaves M. Vincristine inhibits the synthesis of malondialdehyde by human platelets in vitro. Cancer. 1982;49:665–8.CrossRefPubMed
40.
Nakatsuji H, Kishida K, Funahashi T. Three-month treatment with pioglitazone reduces circulating levels of thiobarbituric acid-reacting substances, a marker of reactive oxidative stress, without change in body mass index, in Japanese patients with type 2 diabetes. Atherosclerosis. 2010;212:432–45.CrossRef
41.
Metadata
Title
Comments on “An Investigation into the Serum Thioredoxin, Superoxide Dismutase, Malondialdehyde, and Advanced Oxidation Protein Products in Patients with Breast Cancer”
Authors
Maryam Khoubnasabjafari, MD, PhD
Khalil Ansarin, MD
Abolghasem Jouyban, PharmD, PhD
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6182-y

Other articles of this Special Issue 3/2017

Annals of Surgical Oncology 3/2017 Go to the issue

Gastrointestinal Oncology

Comment on: External Validation of the Simplified Preoperative Assessment for Low-Grade Mucinous Adenocarcinoma of the Appendix

Breast Oncology

Comparison of Indocyanine Green Fluorescence and Blue Dye Methods in Detection of Sentinel Lymph Nodes in Early-Stage Breast Cancer

Health Services Research and Global Oncology

Letters to the Editor Anthology: An e-Supplement Resource

Colorectal Cancer

Comment: Skeletal Muscle Depletion is Associated with Severe Postoperative Complications in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer

Head and Neck Oncology

Reply to: Partial Verification Distorts Estimates of Sensitivity in Diagnostic Accuracy Studies for Fine-Needle Aspiration Cytology

Gastrointestinal Oncology

Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms